A pioneering cannabis-based medicine for multiple sclerosis from
GW Pharmaceuticals has been filed for approval in Europe, paving
the way for its potential approval at the end of 2009 or early
2010.
Following numerous delays, the submission to regulators in Britain
and Spain is a landmark for the British drugmaker, which also
announced on Wednesday it had made a maiden net profit of 4.0
million pounds ($10.3 million) in the six months to March 31 from a
4.2 million loss a year ago.
Shares in the company rose nine percent in early trade.
Clinical trials have shown GW's drug Sativex, which is sprayed
under the tongue, reduces spasticity in multiple sclerosis patients
who do not respond adequately to existing therapies.
If it is approved, Sativex will be marketed in Britain by Germany's
Bayer and in the rest of Europe by Spain's Almirall.
Following the filings in Britain and Spain, submissions for
approval will made in other European countries during 2010.
Sativex became the world's first cannabis medicine to win
regulatory approval when it was approved in Canada in 2005.
But the drug - extracted from marijuana plants, grown at secret
locations in the English countryside - has been hit by a string of
delays in Europe, where GW originally hoped to win approval in
2003.
The spray contains two active cannabinoids, CBD and THC. The latter
substance is responsible for the euphoria associated with smoking
cannabis.
GW also said it was planning a mid-stage Phase II clinical with a
new cannabinoid medicine for the treatment of dyslipidaemia, or
raised levels of fat in the blood, in Type II diabetes
patients.
Cannabis based drug filed for approval
Published: 7:46PM Wednesday May 20, 2009 Source: Reuters
Advertisement
Health & Lifestyle News
- Cancer research inspires young author
- Wanganui Hospital plans cuts to maternity services watch
- opinion Jack Tame: The test
- HIV infected are going undiagnosed - research watch
- Toxic algae warning on Hurunui River
- NZ acne drug to be sold in America
- Magic mushrooms studied for depression treatment
Advertisement
Most Popular
- Boy missing in river now presumed drowned watch
- Beyonce, Jay-Z share first pics of Blue Ivy
- Repeated industrial rope falls 'not good enough' watch
- Evacuations after mall deemed quake risk watch
- Fake security school operator faces prosecution watch
rssLatest News
Advertising
How do you want your news?
-
Email
Choose the news you want when you want it, all in one personalised daily e-mail.
-
Mobile Devices
TVNZ is available on mobile phones: Text TVNZ to 8869.
-
News Feeds
See when TVNZ have added new content. You can get the latest headlines anywhere.
-
Podcasts
Enjoy TVNZ on the move - a wide range of programmes and highlights are available.
Copyright © 2012, Television New Zealand Limited. Breaking and Daily News, Sport & Weather | TV ONE, TV2 | Ondemand